lentiviral gene therapy (Intrexon)

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug Namelentiviral gene therapy (Intrexon)
Drug Alias Namelentiviral gene therapy (Rheogene)
ClassificationBiologics
Mechanisms of ActionDOPA decarboxylase gene transference
TargetsAromatic-L-amino-acid decarboxylase
Therapy Area/IndicationsParkinson Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesRheoGene Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesRheoGene Inc
Active IndicationsN/A
Inactive IndicationsParkinson Disease

Other Information

ATC CodeN/A
Related LinksN/A